studied TMB in ovarian cancer with BRCA1 and BRCA2 and found that TMB coupled with BRCA1 or BRCA2 mutations could be used as a genomic marker of prognosis and a predictor of treatment response53. The gene discussed is BRCA2; the disease is ovarian cancer.